Blueprint Medicines Income from Continuous Operations 2014-2024 | BPMC
Blueprint Medicines income from continuous operations for the twelve months ending September 30, 2024 was $-0.128B, a 76.92% decline year-over-year.
- Blueprint Medicines annual income from continuous operations for 2023 was $-0.507B, a 9.06% decline from 2022.
- Blueprint Medicines annual income from continuous operations for 2022 was $-0.558B, a 13.44% decline from 2021.
- Blueprint Medicines annual income from continuous operations for 2021 was $-0.644B, a 305.2% decline from 2020.